Sanajivani Parenteral Q4 FY26 Consolidated Revenue at ₹138 Crore, PAT at ₹5.48 Lakh
Sanajivani Parenteral reported Q4 FY26 consolidated revenue of ₹138.09 crore and PAT of ₹5.48 lakh. EBITDA was ₹21.73 lakh with a 15.74% margin. The company is addressing logistical challenges impacting shipments and focusing on business expansion and new product development.
The company is experiencing logistical challenges that have impacted recent performance, though it anticipates improvements. The focus on business expansion and new product development suggests potential for future growth, but current results are mixed.
The financial results show both positive operational improvements and challenges related to logistics and shipments. While revenue is reported, the PAT is relatively low, indicating a neutral financial outcome for the quarter.
Sanajivani Parenteral Limited has announced its audited financial results for the fourth quarter and fiscal year 2025-26. The company reported that improvements in various business segments, a customer-centric approach, and efficient execution have strengthened its financial position.
For the fourth quarter, the company's consolidated revenue stood at ₹138.09 crore. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the period was ₹21.73 lakh, with an EBITDA margin of 15.74%. Profit After Tax (PAT) after tax was ₹5.48 lakh, resulting in a PAT margin of 3.97%. The Earnings Per Share (EPS) for the quarter was ₹0.49.
The company highlighted that certain logistical challenges in the supply chain had caused delays in shipments, impacting production and margins. However, the company completed the manufacturing of approximately ₹6 crore worth of finished goods, which are awaiting regulatory approvals for export. Despite these temporary issues, the company improved its operational efficiency by reducing employee and operational costs as a percentage of sales, achieving 242 BPS.
Sanajivani Parenteral also noted the continuous improvement and increasing commercial traction at its Pune IV Fluids plant. Strategic enhancements are underway, and further growth is expected upon receiving additional formulation approvals, customer registrations, and distribution of the first consignment. The Pune plant has commenced commercial operations, with initial shipments valued at approximately USD 0.5 million. Management anticipates significant improvements in profitability and operating margins as the utilization rate of the facility increases.
The company plans to focus on new product development and business expansion in response to evolving market demands.
What to do with a filing like this
Creative Newtech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Creative Newtech Limited. Read the original for the full detail.